Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its IBI363/TAK-928 (PD-1/IL-2α-biased bispecific fusion protein) * , IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC)...
Greenfield Dental Market Insights: Rising Dental Costs Push Thousands of Western Patients to Vietnam
HANOI, Vietnam, Sept. 23, 2026 /PRNewswire/ -- Greenfield Dental has recorded a significant surge in international patient volume with over 300% growth since 2025, reflecting Vietnam's emergence as a premier dental tourism destination and Greenfield's growing reputation. The Greenfield Dental clinical team providing multilingual care to international patients Greenfield Dental: Comprehensive world-class dental care...
RSMC Brings Fertility Insights to Asia This October
HONG KONG, SHANGHAI and SHENZHEN, China, Sept. 23, 2026 /PRNewswire/ -- The Mid-Autumn Festival is a time for family reunions and reflection on the future. As more couples explore international fertility care, understanding their options before beginning treatment has become an important part of family planning. RSMC(Reproductive Sciences Medical Center) in the United States will launch its October Asia...
A New Regional Healthcare Experience Begins in Cambodia, Connecting Families to Care Beyond Borders
PHNOM PENH, Cambodia, Sept. 23, 2026 /PRNewswire/ -- Maybank (Cambodia) Plc., in collaboration with Malaysia Healthcare Travel Council (MHTC), will host MH WellFest Cambodia 2026 on 3 and 4 October 2026 at Borey Peng Huoth Eco Park in Phnom Penh. Endorsed by the Embassy of Malaysia in Phnom Penh, the event will...
Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum’s Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for Lipedema, a condition affecting approximately 10% of women globally and representing a market opportunity of...
Novo receives Singapore approval for Wegovy® as first treatment for MASH with liver fibrosis
ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with 34% receiving placebo, at Week 72. Singapore's Health Sciences Authority (HSA) has approved Wegovy® (once-weekly injectable semaglutide 2.4 mg) as the first approved treatment in Singapore for adults with noncirrhotic metabolic...
GROWNSY Makes NANN Conference Debut, Partners with NANN and Pediatrician Dr. Molly O’Shea on NANNcast Episode Tackling Infant Nasal Congestion
The company exhibited for the first time at NANN's 42nd Annual Conference in West Palm Beach and will sponsor a NANNcast episode exploring why newborns are so vulnerable to nasal congestion — and what neonatal nurses and parents can do about it. NEW YORK, Sept. 23, 2026 /PRNewswire/ -- GROWNSY, a baby care innovator trusted by over 3...
Mayo Clinic Laboratories Invests in Pathology Asia Holdings and LifeStrands Genomics to Advance Diagnostics and Precision Medicine
SINGAPORE, Sept. 23, 2026 /PRNewswire/ -- Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand. Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together...
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera’s MPER-Targeting HIV-1 Program
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. MPER vaccine immunogens elicit antibody levels approximately five times those of the study...
Tsingke Enables High-Throughput Validation of AI-Designed Proteins and Antibodies
BEIJING, Sept. 22, 2026 /PRNewswire/ -- Tsingke today announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed proteins and antibodies. Combining gene synthesis, parallel expression, high-throughput screening, scale-up production, purification and quantitative binding analysis, the workflow enables researchers to move large numbers of computationally designed candidates into experimental testing and advance...
